Kodiak Sciences Inc. $KOD Stock Holdings Decreased by RIA Advisory Group LLC

RIA Advisory Group LLC reduced its position in Kodiak Sciences Inc. (NASDAQ:KOD) by 31.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 113,473 shares of the company’s stock after selling 53,061 shares during the period. Kodiak Sciences comprises approximately 0.8% of RIA Advisory Group LLC’s holdings, making the stock its 24th largest position. RIA Advisory Group LLC owned approximately 0.21% of Kodiak Sciences worth $3,173,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. GF Fund Management CO. LTD. purchased a new position in shares of Kodiak Sciences in the fourth quarter worth approximately $29,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Kodiak Sciences in the fourth quarter worth approximately $72,000. Strs Ohio acquired a new stake in shares of Kodiak Sciences during the fourth quarter worth approximately $87,000. BNP Paribas Financial Markets boosted its holdings in shares of Kodiak Sciences by 89.4% during the third quarter. BNP Paribas Financial Markets now owns 6,373 shares of the company’s stock worth $104,000 after purchasing an additional 3,009 shares during the period. Finally, Diversified Trust Co. acquired a new stake in shares of Kodiak Sciences during the fourth quarter worth approximately $219,000. 89.06% of the stock is owned by hedge funds and other institutional investors.

Kodiak Sciences Stock Performance

KOD stock opened at $43.96 on Friday. The stock has a market cap of $2.73 billion, a P/E ratio of -10.18 and a beta of 2.32. The firm has a 50 day simple moving average of $33.92 and a 200 day simple moving average of $26.88. Kodiak Sciences Inc. has a 52 week low of $2.81 and a 52 week high of $47.84.

Kodiak Sciences (NASDAQ:KOD) last posted its earnings results on Tuesday, March 31st. The company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.02). Sell-side analysts predict that Kodiak Sciences Inc. will post -3.65 EPS for the current year.

Analyst Upgrades and Downgrades

KOD has been the subject of several research reports. UBS Group raised their price target on shares of Kodiak Sciences from $50.00 to $80.00 and gave the stock a “buy” rating in a report on Friday, March 27th. HC Wainwright restated a “buy” rating and set a $58.00 price target (up from $38.00) on shares of Kodiak Sciences in a report on Friday, March 27th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Kodiak Sciences in a report on Thursday, January 22nd. Five equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Kodiak Sciences currently has an average rating of “Moderate Buy” and an average target price of $35.43.

Kodiak Sciences Profile

Kodiak Sciences, Inc is a clinical‐stage biopharmaceutical company headquartered in Palo Alto, California, that focuses on the discovery and development of novel therapies for retinal diseases. The company’s proprietary technology centers on antibody biopolymer conjugates (ABCs), which are designed to extend durability, enhance tissue penetration and improve the safety profile of existing therapeutic modalities. Kodiak’s research and development efforts target conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and other serious ophthalmic disorders.

The lead product candidate in Kodiak’s pipeline is KSI-301, an anti-VEGF antibody biopolymer conjugate administered via intravitreal injection.